Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Crump

Showing results (151-160 of 183) with videos related to

Pageof 19
Sort By:
Journal of the National Cancer Institute|April 15, 2015
Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12Matthew C Cheung, Annette E Hay, Michael Crump, et al.
Blood|June 26, 2015
Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12John Kuruvilla, David A MacDonald, C Tom Kouroukis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2011
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL studyOwen A O'Connor, Barbara Pro, Lauren Pinter-Brown, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 5, 2014
Methods for sample acquisition and processing of serial blood and tumor biopsies for multicenter diffuse large B-cell lymphoma clinical trialsTorsten Holm Nielsen, Zuanel Diaz, Rosa Christodoulopoulos, et al.
Blood Advances|September 3, 2021
Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphomaSattva S Neelapu, Frederick L Locke, Nancy L Bartlett, et al.
The Lancet. Oncology|December 26, 2017
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trialOwen A O'Connor, Jennifer K Lue, Ahmed Sawas, et al.
Hepatology Communications|December 3, 2025
Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trialSanam Tabataba Vakili, Grishma Hirode, Atif Zahoor, et al.
Blood Advances|November 20, 2020
A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville scoreHo-Young Yhim, Yael Eshet, Ur Metser, et al.
British Journal of Haematology|August 7, 2024
Single gene mutations and prognosis in limited-stage follicular lymphoma treated with radiation therapySamantha A Hershenfeld, Josuha W D Tobin, Victoria Shelton, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 22, 2014
Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphomaDiego Villa, Anupkumar George, John F Seymour, et al.
Pageof 19

Showing results (151-160 of 183) with videos related to

Sort By:
Pageof 19
Journal of the National Cancer Institute|April 15, 2015
Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12Matthew C Cheung, Annette E Hay, Michael Crump, et al.
Blood|June 26, 2015
Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12John Kuruvilla, David A MacDonald, C Tom Kouroukis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2011
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL studyOwen A O'Connor, Barbara Pro, Lauren Pinter-Brown, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 5, 2014
Methods for sample acquisition and processing of serial blood and tumor biopsies for multicenter diffuse large B-cell lymphoma clinical trialsTorsten Holm Nielsen, Zuanel Diaz, Rosa Christodoulopoulos, et al.
Blood Advances|September 3, 2021
Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphomaSattva S Neelapu, Frederick L Locke, Nancy L Bartlett, et al.
The Lancet. Oncology|December 26, 2017
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trialOwen A O'Connor, Jennifer K Lue, Ahmed Sawas, et al.
Hepatology Communications|December 3, 2025
Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trialSanam Tabataba Vakili, Grishma Hirode, Atif Zahoor, et al.
Blood Advances|November 20, 2020
A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville scoreHo-Young Yhim, Yael Eshet, Ur Metser, et al.
British Journal of Haematology|August 7, 2024
Single gene mutations and prognosis in limited-stage follicular lymphoma treated with radiation therapySamantha A Hershenfeld, Josuha W D Tobin, Victoria Shelton, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 22, 2014
Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphomaDiego Villa, Anupkumar George, John F Seymour, et al.
Pageof 19